Investment analysts at Chardan Capital initiated coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report issued on Monday. The brokerage set a “buy” rating and a $12.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 31.15% from the stock’s current price.
Several other equities research analysts have also commented on ARCT. Roth Capital lowered shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $4.00 to $1.00 in a research report on Friday, September 29th. WBB Securities upgraded shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Monday, October 9th. Zacks Investment Research upgraded shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Wednesday, October 4th. Finally, Ladenburg Thalmann Financial Services began coverage on shares of Arcturus Therapeutics in a research report on Wednesday, November 29th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $3.08.
Shares of Arcturus Therapeutics (NASDAQ:ARCT) opened at $9.15 on Monday. The company has a market cap of $96.71, a price-to-earnings ratio of -2.29 and a beta of 1.55. Arcturus Therapeutics has a 1 year low of $6.51 and a 1 year high of $15.19.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.